'Learn from the lessons and don't forget them': identifying transferable lessons for COVID-19 from meningitis A, yellow fever and Ebola virus disease vaccination campaigns. 2021

Julie Collins, and Rosie Westerveld, and Kate A Nelson, and Hana Rohan, and Hilary Bower, and Siobhan Lazenby, and Gloria Ikilezi, and Rebecca Bartlein, and Daniel G Bausch, and David S Kennedy
UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine/Public Health England, London, UK julie.collins@lshtm.ac.uk.

COVID-19 vaccines are now being distributed to low- and middle-income countries (LMICs), with global urgency surrounding national vaccination plans. LMICs have significant experience implementing vaccination campaigns to respond to epidemic threats but are often hindered by chronic health system challenges. We sought to identify transferable lessons for COVID-19 vaccination from the rollout of three vaccines that targeted adult groups in Africa and South America: MenAfriVac (meningitis A); 17D (yellow fever) and rVSV-ZEBOV (Ebola virus disease). We conducted a rapid literature review and 24 semi-structured interviews with technical experts who had direct implementation experience with the selected vaccines in Africa and South America. We identified barriers, enablers, and key lessons from the literature and from participants' experiences. Interview data were analysed thematically according to seven implementation domains. Participants highlighted multiple components of vaccination campaigns that are instrumental for achieving high coverage. Community engagement is an essential and effective tool, requiring dedicated time, funding and workforce. Involving local health workers is a key enabler, as is collaborating with community leaders to map social groups and tailor vaccination strategies to their needs. Vaccination team recruitment and training strategies need to be enhanced to support vaccination campaigns. Although recognised as challenging, integrating vaccination campaigns with other routine health services can be highly beneficial if well planned and coordinated across health programmes and with communities. As supplies of COVID-19 vaccines become available to LMICs, countries need to prepare to efficiently roll out the vaccine, encourage uptake among eligible groups and respond to potential community concerns. Lessons from the implementation of these three vaccines that targeted adults in LMICs can be used to inform best practice for COVID-19 and other epidemic vaccination campaigns.

UI MeSH Term Description Entries
D008581 Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6) Pachymeningitis,Meningitides,Pachymeningitides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000086663 COVID-19 Vaccines Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19. 2019 Novel Coronavirus Vaccine,2019 Novel Coronavirus Vaccines,2019-nCoV Vaccine,2019-nCoV Vaccines,COVID 19 Vaccine,COVID-19 Vaccine,COVID-19 Virus Vaccine,COVID-19 Virus Vaccines,COVID19 Vaccine,COVID19 Vaccines,COVID19 Virus Vaccine,COVID19 Virus Vaccines,Coronavirus Disease 2019 Vaccine,Coronavirus Disease 2019 Vaccines,Coronavirus Disease 2019 Virus Vaccine,Coronavirus Disease 2019 Virus Vaccines,Coronavirus Disease-19 Vaccine,Coronavirus Disease-19 Vaccines,SARS Coronavirus 2 Vaccines,SARS-CoV-2 Vaccine,SARS-CoV-2 Vaccines,SARS2 Vaccine,SARS2 Vaccines,2019 nCoV Vaccine,2019 nCoV Vaccines,COVID 19 Vaccines,COVID 19 Virus Vaccine,COVID 19 Virus Vaccines,Coronavirus Disease 19 Vaccine,Coronavirus Disease 19 Vaccines,SARS CoV 2 Vaccine,SARS CoV 2 Vaccines,Vaccine, 2019-nCoV,Vaccine, COVID 19,Vaccine, COVID-19,Vaccine, COVID-19 Virus,Vaccine, COVID19,Vaccine, COVID19 Virus,Vaccine, Coronavirus Disease-19,Vaccine, SARS-CoV-2,Vaccine, SARS2,Vaccines, 2019-nCoV,Vaccines, COVID-19,Vaccines, COVID-19 Virus,Vaccines, COVID19,Vaccines, COVID19 Virus,Vaccines, Coronavirus Disease-19,Vaccines, SARS-CoV-2,Vaccines, SARS2,Virus Vaccine, COVID-19,Virus Vaccine, COVID19,Virus Vaccines, COVID-19,Virus Vaccines, COVID19
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015004 Yellow Fever An acute infectious disease primarily of the tropics, caused by a virus and transmitted to man by mosquitoes of the genera Aedes and Haemagogus. The severe form is characterized by fever, HEMOLYTIC JAUNDICE, and renal damage. Fever, Yellow,Fevers, Yellow,Yellow Fevers
D017589 Immunization Programs Organized services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international. Vaccination Awareness,Vaccination Campaign,Vaccination Promotion,Awareness, Vaccination,Awarenesses, Vaccination,Campaign, Vaccination,Campaigns, Vaccination,Immunization Program,Program, Immunization,Programs, Immunization,Promotion, Vaccination,Promotions, Vaccination,Vaccination Awarenesses,Vaccination Campaigns,Vaccination Promotions
D046129 Ebola Vaccines Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER. Ebola Vaccine,Ebola Virus Vaccine,Ebola Virus Vaccines,Ebolavirus Vaccine,Ebolavirus Vaccines,Vaccine, Ebola,Vaccine, Ebola Virus,Vaccine, Ebolavirus,Vaccines, Ebola,Vaccines, Ebola Virus,Vaccines, Ebolavirus,Virus Vaccine, Ebola,Virus Vaccines, Ebola
D019142 Hemorrhagic Fever, Ebola A highly fatal, acute hemorrhagic fever caused by EBOLAVIRUS. Ebola Hemorrhagic Fever,Ebola Virus Disease,Ebolavirus Infection,Ebola Infection,Ebola Virus Infection,Ebolavirus Infections,Infection, Ebola,Infection, Ebola Virus,Infection, Ebolavirus,Infections, Ebolavirus,Virus Infection, Ebola

Related Publications

Julie Collins, and Rosie Westerveld, and Kate A Nelson, and Hana Rohan, and Hilary Bower, and Siobhan Lazenby, and Gloria Ikilezi, and Rebecca Bartlein, and Daniel G Bausch, and David S Kennedy
January 1995, Medecine tropicale : revue du Corps de sante colonial,
Julie Collins, and Rosie Westerveld, and Kate A Nelson, and Hana Rohan, and Hilary Bower, and Siobhan Lazenby, and Gloria Ikilezi, and Rebecca Bartlein, and Daniel G Bausch, and David S Kennedy
July 2022, Pathogens (Basel, Switzerland),
Julie Collins, and Rosie Westerveld, and Kate A Nelson, and Hana Rohan, and Hilary Bower, and Siobhan Lazenby, and Gloria Ikilezi, and Rebecca Bartlein, and Daniel G Bausch, and David S Kennedy
December 2022, Emerging infectious diseases,
Julie Collins, and Rosie Westerveld, and Kate A Nelson, and Hana Rohan, and Hilary Bower, and Siobhan Lazenby, and Gloria Ikilezi, and Rebecca Bartlein, and Daniel G Bausch, and David S Kennedy
December 2017, Emerging infectious diseases,
Julie Collins, and Rosie Westerveld, and Kate A Nelson, and Hana Rohan, and Hilary Bower, and Siobhan Lazenby, and Gloria Ikilezi, and Rebecca Bartlein, and Daniel G Bausch, and David S Kennedy
October 2022, Journal of global health,
Julie Collins, and Rosie Westerveld, and Kate A Nelson, and Hana Rohan, and Hilary Bower, and Siobhan Lazenby, and Gloria Ikilezi, and Rebecca Bartlein, and Daniel G Bausch, and David S Kennedy
January 2020, Ethics, medicine, and public health,
Julie Collins, and Rosie Westerveld, and Kate A Nelson, and Hana Rohan, and Hilary Bower, and Siobhan Lazenby, and Gloria Ikilezi, and Rebecca Bartlein, and Daniel G Bausch, and David S Kennedy
January 2022, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine,
Julie Collins, and Rosie Westerveld, and Kate A Nelson, and Hana Rohan, and Hilary Bower, and Siobhan Lazenby, and Gloria Ikilezi, and Rebecca Bartlein, and Daniel G Bausch, and David S Kennedy
April 2018, The Lancet. Infectious diseases,
Julie Collins, and Rosie Westerveld, and Kate A Nelson, and Hana Rohan, and Hilary Bower, and Siobhan Lazenby, and Gloria Ikilezi, and Rebecca Bartlein, and Daniel G Bausch, and David S Kennedy
May 2022, Cell reports methods,
Julie Collins, and Rosie Westerveld, and Kate A Nelson, and Hana Rohan, and Hilary Bower, and Siobhan Lazenby, and Gloria Ikilezi, and Rebecca Bartlein, and Daniel G Bausch, and David S Kennedy
July 2020, Oman medical journal,
Copied contents to your clipboard!